4/21/2021

speaker
Gary
Conference Specialist

Good afternoon, and welcome to Synthetic Biologics 2020 Year-End Investor Conference Call. All participants will be in listen-only mode. Should you need assistance, please signal a conference specialist by pressing the star key followed by zero. After today's presentation, there will be an opportunity to ask questions. To ask a question, you may press star, then one on your telephone keypad. To withdraw your question, please press star, then two. Please note, this event is being recorded. At this time, I would like to turn the call over to Vincent Perrone, Director of Corporate Communication at Synthetic Biologics. Please go ahead.

speaker
Vincent Perrone
Director of Corporate Communication

Thanks, Gary, and good afternoon, everyone. Welcome to Synthetic Biologics 2020 Year-End Investor Conference Call. Today, I'm joined remotely by Stephen Shawcross, Chief Executive and Financial Officer, Dr. Michael Calico, Senior Vice President, Research and Development, and Dr. Vince Wager, head of product and corporate development. Synthetic Biologics issued a press release this afternoon, which provided operational highlights and reported our financial results for the year ending December 31st, 2020. The release can be found on the investor relations section of our website. During our call today, we'll provide an operational update on our GI and microbiome-focused clinical programs and summarize our financial results. We'll take questions after prepared remarks. In addition to the phone line, this call will be streamed live via webcast and will be archived on our website at www.syntheticbiologics.com for 90 days. During this call, we will be making forward-looking statements regarding Synthetic Biologics' current expectations and projections about future events. Generally, the forward-looking statements can be identified by terminology such as may, should, expects, anticipates, intends, plans, believes, estimates, and similar expressions. These statements are based upon current beliefs, expectations, and assumptions and are subject to a number of risks and uncertainties, including those set forth in synthetic biologics violence with the SEC, many of which are difficult to predict. No forward-looking statements can be guaranteed, and actual results may differ materially from such statements. The information on this call is provided only as of the date of this call, and synthetic biologics undertakes no obligation to update any forward-looking statements contained on this conference call on account of new information, future events, or otherwise, except as required by law. With that, I'd like to turn the call over to Steve. Steve?

speaker
Stephen Shawcross
Chief Executive Officer & Financial Officer

Thanks, Vincent. Good afternoon, everyone, and thank you for joining our 2020 year-end investor conference call. I hope everyone is staying safe and healthy as we continue to navigate the global health crisis sparked by the COVID-19 pandemic. It was a busy year, and the start of the new year for the CIN team. I'm very excited to be with you this afternoon to share our operational highlights and financial results. I'd like to start our call by saying that we are more encouraged than ever by the outlook for our business. We've made important progress this year by advancing and demonstrating the significant value of our pipeline of GI and microbiome folks clinical programs. And as we look ahead into 2021 and 2022, there are more reasons than ever to be excited about our company's future prospects. Before I give you an update on our two lead clinical programs, I'd like to provide a brief recap of several operational milestones which have unquestionably allowed us to strengthen our balance sheet and position our company for what I believe will be significant long-term growth, as well as the delivery of multiple short and long-term clinical milestones. Starting in January, favorable market conditions triggered the exercise or the cash exercise of approximately 65 percent of the warrants associated with our 2018 public financing and allowed us to efficiently utilize our at-the-market facility. In addition, The conversion of all of our outstanding shares of Series A and Series B convertible preferred stock into common stock have not only further helped streamline our capital structure and balance sheet, but allowed us to position the company to meet the conditions to fully regain NYSE listing compliance. As a result of these activities, we're pleased to announce that our current cash balance is approximately $72.6 million. the strongest cash position in the company's history. Our strength in financial position now provides us with the runway to continue our operations well into 2023. Importantly, we now have the financial foundation to fully fund our Phase 1b-2a clinical trial of SIN4 and planned Phase 1 and Phase 2 clinical studies of SIN20. In addition, we are now positioned to evaluate and potentially acquire new technologies and or assets intended to enhance our development pipeline, which we believe may benefit from our incredibly experienced team. As we anticipate clinical trials returning to normal, our recently strengthened financial position will allow us to conduct multiple clinical studies during the next several years advancing our portfolio of GI-focused clinical programs through proof of concept. As we think about the remainder of 2021 and moving into 2022, we are excited about several potential catalysts and clinical milestones that can create additional significant value for our shareholders. Specifically, for SYN4, our therapy and development to prevent acute graft-versus-host disease, or AGVHD, We are excited to announce that Washington University has begun screening patients for enrollment of the first cohort in the Phase 1b2a clinical trial in L-Geneic Metabiotic Cell Transplant, or HCT, recipients. We expect to begin dosing patients in this cohort before the end of the month and if enrollment proceeds as planned. we will be positioned to announce up to three interim data readouts during the next 12 to 18 months, with the first one anticipated before the end of the year, pandemic conditions permitting. For SYN20, our intestinal alpha-mphosphatase program, a phase one single ascending dose study, or SAD study, is expected to begin during the second quarter. A top line readout for this clinical trial is expected during the third quarter of 2021 and a second phase one multiple ascending dose study or MAD study of CIN20 is expected to begin in Q3 with top line data expected in Q1 of next year. Both phase one trials are designed to support the development of CIN20 in multiple clinical indications. Following what we believe will be a successful Phase I program, we are preparing a Phase II clinical study in celiac patients, as well as clinical programs for other potential indications that could begin as soon as early 2022. We believe CIN4 in development to prevent AGVHD and CIN20, a recombinant intestinal alkaline phosphatase program, address very sizable and underserved markets, and have the potential to be foundational, long-term drivers of value for our company and our shareholders. With that backdrop, I'd like to provide an update on our clinical development activities, beginning with our SYN4 or ribaximase program. SYN4 is our first-in-class therapeutic intervention designed to protect the gut microbiome from antibiotic-mediated dysbiosis. We believe protection of the gut microbiome may play a pivotal role in improving health outcomes for patients administered long courses of intravenous beta-lactam antibiotics as part of their treatment plan for bone marrow and solid organ transplantations. Elgin egg HCT recipients routinely receive long courses of IV beta-lactam antibiotics to treat neutropenic fever, which occurs in 80 to 90 percent of the patients. Microbiome damage from IV beta-lactam antibiotics is associated with AGVHD, VI recolonization, bacteremia, and C. difficile infection. AGVHD occurs in 30 to 60% of L-genetic HCC recipients and is a leading cause of graft failure and mortality. Prevention of AGVHD is absolutely critical in this patient population. since first-line AGVHD steroid therapies fail in more than 50% of the patients, resulting in two-year survival rates of around 20%. The use of SYN4 in L-genetic HCT patients is well supported by our existing clinical data, and SYN4's potential to preserve the intestinal microbiome in L-genetic HCT recipients could provide remarkable benefits to patients, providers, and payers. Estimates of in-hospital costs for L-genetic HCT recipients in the U.S. range from $180,000 to more than $300,000. All-cause inpatient and outpatient costs are estimated to be greater than $600,000 per patient when measured up to 12 months after hospital admission. At least one U.S. study found that L-genetic HCT recipients who developed AGVHD had a three times higher in-hospital mortality rate and almost two-fold increase in higher median hospital costs than patients who did not develop AGVHD. If SYNFORM could reduce AGVHD incidence by 30%, it may provide significant improvements in patient outcomes including prevention of an average of 11 deaths and a reduction of $4.3 million in hospital treatment costs per 1,000 patients. In 2018, there were approximately 29,000 L-genetic ACT procedures conducted in the US and Europe, and an additional 13,000 procedures conducted in Japan and China. While these are comparatively small patient numbers, the substantial potential benefits Sinform may provide in this patient population could allow for premium pricing and significant market value. Conservatively, our modeling suggests a revenue opportunity in the U.S. and European markets of more than $800 million in the first five years of sales when considering pricing of $1,000 a day for 14 days of treatment. if we were able to expand the opportunity for SIN4 use in solid organ transplant recipients, the market opportunity could be four times larger. It is worth noting that developing SIN4 for use in this specific patient population may also provide an opportunity to seek orphan drug designation, which may further facilitate Phase III clinical developments. Last year, we outlined our plan to move this program forward in collaboration with our clinical development partner, the Washington University School of Medicine in St. Louis, in the form of a Phase 1b-2a clinical trial of SYN4 and L-genetic HCT recipients. The goal of this study is to evaluate the safety, tolerability, and pharmacokinetics of SYN4 administered to as many as 36 adult L-genetic HCT recipients who receive an who receive a beta-lactam antibiotic to treat fever. Participants will be enrolled in three sequential cohorts that will be administered a different IV beta-lactam antibiotic. Eight participants in each cohort will receive SYN4 and four will receive placebo. Patients enrolled in the first antibiotic cohort will receive the antibiotic meropenem, which is not degraded by SYN4, in order to determine whether SYN4 is systemically absorbed in this patient population. Pharmacokinetic data from our previously completed phase one and phase two clinical trials provided supporting evidence that SYN4 should not affect the IV antibiotic in the bloodstream. If we see that SYN4 is not systemically absorbed in this first cohort, will consider applying for orphan drug designation and begin to prepare for our phase three program as the remainder of this clinical trial completes. At this time, Washington University is currently screening patients for enrollment in this first cohort, and dosing of the first patient is expected to take place this month. If enrollment proceeds as planned, a top line data readout for the first cohort may be available before the end of the year. Next, I'd like to turn the call over to my colleague, Dr. Michael Calico, who will provide an update on our CIN20 intestinal alkaline phosphatase, or IAP program, which is currently being developed as a treatment for celiac disease, as well as other potential GI and systemic inflammatory and age-related disorders. Mike?

Disclaimer

This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.

-

-